1
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)
Condition(s):Myelofibrosis; Chronic Myelomonocytic Leukemia; Acute Myeloid LeukemiaLast Updated:July 19, 2022Recruiting
Elzonris: 6 Clinical Trials
Hide Studies Not Open or Pending
2
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Condition(s):Hematologic Malignancy; AML; ALL; BPDCN; MDS; Lymphoblastic Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Hodgkin Lymphoma; Mixed Phenotype Acute Leukemia; Acute Undifferentiated LeukemiaLast Updated:July 27, 2022Not yet recruiting
3
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:April 15, 2022Active, not recruiting
4
Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia
Condition(s):Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2; Myelodysplastic/Myeloproliferative NeoplasmLast Updated:March 7, 2022Recruiting
5
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Condition(s):Recurrent Adult Lymphoblastic Lymphoma; Recurrent B Acute Lymphoblastic Leukemia; Recurrent T Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory Lymphoblastic Lymphoma; Refractory T Acute Lymphoblastic LeukemiaLast Updated:July 12, 2022Recruiting
6
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:December 2, 2021Recruiting